Chen, P.; Wang, M.; Peng, S.; Zhu, H.; Wang, Y.; Wan, Z.; Yang, X.; Yu, Z.; Zhou, Y.
Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. Curr. Oncol. 2026, 33, 173.
https://doi.org/10.3390/curroncol33030173
AMA Style
Chen P, Wang M, Peng S, Zhu H, Wang Y, Wan Z, Yang X, Yu Z, Zhou Y.
Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. Current Oncology. 2026; 33(3):173.
https://doi.org/10.3390/curroncol33030173
Chicago/Turabian Style
Chen, Ping, Mengchi Wang, Siyan Peng, Honglin Zhu, Yanming Wang, Zixuan Wan, Xuan Yang, Zhixin Yu, and Yixin Zhou.
2026. "Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma" Current Oncology 33, no. 3: 173.
https://doi.org/10.3390/curroncol33030173
APA Style
Chen, P., Wang, M., Peng, S., Zhu, H., Wang, Y., Wan, Z., Yang, X., Yu, Z., & Zhou, Y.
(2026). Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. Current Oncology, 33(3), 173.
https://doi.org/10.3390/curroncol33030173
